← Back to headlines
Barclays Assigns Overweight Rating to SAB Biotherapeutics Inc.
Barclays has issued an 'Overweight' rating for SAB Biotherapeutics Inc. (SABS), indicating a positive outlook for the company's stock.
30 Jun, 16:34 — 30 Jun, 16:34
Sources
Showing 1 of 1 sources
Related Stories
Corporate Dividend Declarations Include Nvidia, Mosaic, and Alamos Gold
21m ago
Build-A-Bear Slashes Revenue Forecast and Replaces Executive After Summer Sales Miss
22m ago
Major Canadian Banks Report Strong Third-Quarter Earnings, Beating Forecasts
47m ago
Anthropic Introduces Framework for AI Agents to Control Physical Devices
1h ago